Debate Assesses FLOT vs CROSS in GEJ Adenocarcinoma
In Partnership With
Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.
Yanghee Woo, MD, surgical oncologist in the Division of Surgical Oncology, associate professor in the Department of Surgery, vice chair of international affairs, director of the Gastroenterology and Minimally Invasive Therapies Program at City of Hope, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma. This debate occurred during the 2024 Society of Surgical Oncology (SSO) Annual Meeting.
The debate specifically focused on the FLOT chemotherapy regimen, which consists of fluorouracil, leucovorin, oxaliplatin, and docetaxel, and the CROSS chemoradiation regimen which consists of of carboplatin and paclitaxel for 5 weeks and concurrent radiotherapy, followed by surgery (chemo XRT). Both of these regimens have become standards of care for this patient population based on trials that were done in 2012 and 2017.
Woo debated on the side of the CROSS regimen for patients with gastroesophageal junction adenocarcinoma while Matthew R. Porembka, MD, associate professor, University of Texas Southwestern Medical Center, argued in favor of FLOT.
Transcription:
0:09 | The debate was talking about FLOT vs CROSS regiments, and I think it brings up the standard of care that was provided for the randomized control trials. The CROSS trial [compared] chemo XRT plus surgery vs surgery alone, which was in 2012.
0:34 | Then FLOT is perioperative, the triple regiment with [fluorouracil, leucovorin, oxaliplatin, and docetaxel, which was published in 2017. These 2 regimens have become the standard of care for gastroesophageal junction adenocarcinoma.
1:03 | However, there are nuances to the studies that were discussed more in detail, and now we have CheckMate 577 [NCT02743494] adding adjuvant nivolumab [Opdivo]. Then we have some evidence about the comparative outcomes of CROSS or CROSS vs perioperative chemotherapy, including [epirubicin, cisplatin plus capecitabine or fluorouracil (Medical Research Council Adjuvant Gastric Infusional Chemotherapy, MAGIC)] plus the FLOT.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
